Pharvaris Announces Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at Upcoming Scientific Meetings

Pharvaris N.V.
Pharvaris N.V.
Pharvaris N.V.
4 min read

In This Article:

ZUG, Switzerland, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to prevent and treat hereditary angioedema (HAE) attacks, today announced the acceptance of multiple abstracts at several upcoming scientific meetings. Presentation details are as follows:

American College of Allergy, Asthma, & Immunology’s Annual Scientific Meeting (ACAAI), Boston, October 24-28, 2024. Seven abstracts have been accepted for e-Poster presentation:

  • Poster: Long-Term Safety and Efficacy of Oral Deucrictibant for Hereditary Angioedema Prophylaxis: CHAPTER-1 Open-Label Extension Study
    Speaker: John Anderson, M.D.
    Format: e-Poster (R102)
    Date, Time: Friday, Oct. 25, 2:00-2:15 p.m. EDT
    Location: Monitor 21, Exhibit Hall A

  • Poster: Long-Term Treatment of Hereditary Angioedema Attacks With Oral Deucrictibant: RAPIDe-2 Extension Study Results
    Speaker: John Anderson, M.D.
    Format: e-Poster (R103)
    Date, Time: Friday, Oct. 25, 2:15-2:30 p.m. EDT
    Location: Monitor 21, Exhibit Hall A

  • Poster: Development Of A Novel Kinin Biomarker Assay For Characterization Of Bradykinin-Mediated Disorders
    Speaker: Evangelia Pardali, Ph.D.
    Format: e-Poster (R088)
    Date, Time: Friday, Oct. 25, 2:30-2:45 p.m. EDT
    Location: Monitor 20, Exhibit Hall A

  • Poster: Development of a HMWK Capillary Immunoblotting Assay for Characterization of Bradykinin-Mediated Disorders
    Speaker: Evangelia Pardali, Ph.D.
    Format: e-Poster (R090)
    Date, Time: Friday, Oct. 25, 3:00-3:15 p.m. EDT
    Location: Monitor 20, Exhibit Hall A

  • Poster: The Bradykinin Challenge Model In Non-Human Primates Successfully Predicted Efficacious Doses of Deucrictibant in Humans
    Speaker: Juan Bravo, Ph.D.
    Format: e-Poster (R112)
    Date, Time: Friday, Oct. 25, 4:30-4:45 p.m. EDT
    Location: Monitor 21, Exhibit Hall A

  • Poster: CHAPTER-1 Phase 2 Trial of Oral Bradykinin B2 Receptor Antagonist Deucrictibant for Hereditary Angioedema Prophylaxis
    Speaker: H. James Wedner, M.D.
    Format: e-Poster (R100)
    Date, time: Friday, Oct. 25, 5:30-5:45 p.m. EDT
    Location: Monitor 20, Exhibit Hall A

  • Poster: Prophylactic Treatment With Oral Deucrictibant Improves Hereditary Angioedema Disease Control and Health-Related Quality of Life
    Speaker: H. James Wedner, M.D.
    Format: e-Poster (R101)
    Date, Time: Friday, Oct. 25, 5:45-6:00 p.m. EDT
    Location: Monitor 20, Exhibit Hall A

Canadian Society of Allergy and Clinical Immunology (CSACI), Banff, Alberta, Canada, November 6-9, 2024. Three abstracts have been accepted for poster presentation.

Recommended Stories